|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|
| Revenue | ||
| Other gains | ||
| Total income | ||
| Raw materials and consumables expenses | ||
| External selling and distribution expenses | ||
| External research and development expenses | ||
| Personnel expenses | ||
| Other administrative expenses | ||
| Other losses | ||
| EBITDA | ||
| Impairment losses on intangible assets | ||
| Change in fair value of contingent consideration | ||
| Impairment expense | ||
| Amortization and depreciation expense | ||
| Operating result | ||
| Financial income | ||
| Financial expense | ||
| Net loss before taxes | ||
| Income taxes | ||
| Net loss for the period | ||
| OTHER COMPREHENSIVE INCOME | ||
| Remeasurement of defined benefit obligations | ||
| Items that will not be reclassified to profit or loss | ||
| Currency translation differences | ||
| Items that may be reclassified to profit or loss | ||
| Other comprehensive income for the period, net of tax | ||
| Total comprehensive loss for the period | ||
| EARNINGS PER SHARE | ||
| Basic loss per share (in CHF) | ||
| Diluted loss per share (in CHF) |
Loading...
